U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C2H4NO2.Cu
Molecular Weight 211.663
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CUPRIC GLYCINATE

SMILES

[Cu++].NCC([O-])=O.NCC([O-])=O

InChI

InChIKey=VVYPIVJZLVJPGU-UHFFFAOYSA-L
InChI=1S/2C2H5NO2.Cu/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper dihydroxide also known as Schweizer's Reagent dissolves cellulose; used in rayon production.

CNS Activity

Curator's Comment: Known to be CNS active in zebrafish. Human data not available.

Originator

Sources: http://pubs.acs.org/doi/abs/10.1021/ja01512a012Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
COPPER•MAX

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Preventing
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
Copper Fluoride Luminescence during UV Photofragmentation of Bis(1,1,1,5,5,5-hexafluoro-2,4-pentanedionato)copper(II) in the Gas Phase.
1996 Aug 14
Copper oxide nanoparticles induce oxidative stress and cytotoxicity in airway epithelial cells.
2009 Oct
Generation of oxidant response to copper and iron nanoparticles and salts: Stimulation by ascorbate.
2009 Oct 30
Copper-promoted coupling of vinyl boronates and alcohols: a mild synthesis of allyl vinyl ethers.
2010 Feb 3
Copper sulfide nanoparticles for photothermal ablation of tumor cells.
2010 Oct
Rapid free chlorine decay in the presence of Cu(OH)2: chemistry and practical implications.
2011 Oct 15
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Probing the chemical nature of dihydrogen complexation to transition metals, a gas phase case study: H2-CuF.
2013 Jan 18
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
A Facile Strategy for Catalyst Separation and Recycling Suitable for ATRP of Hydrophilic Monomers Using a Macroligand.
2016 Jan
Patents

Sample Use Guides

In Vivo Use Guide
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration: Intravenous
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Name Type Language
CUPRIC GLYCINATE
GREEN BOOK  
Common Name English
COPPER(II) GLYCINATE
Systematic Name English
BIS(GLYCINATO-N,O)COPPER
Common Name English
Copper glycinate [WHO-DD]
Common Name English
CUPRIC BISGLYCINATE
MI  
Common Name English
CUPRIC BISGLYCINATE [MI]
Common Name English
COPPER GLYCINATE [INCI]
Common Name English
COPPER GLYCINATE
INCI   WHO-DD  
INCI  
Official Name English
CUPRIC GLYCINATE [GREEN BOOK]
Common Name English
NSC-162736
Code English
COPPER(II) BISGLYCINATE
Systematic Name English
Classification Tree Code System Code
CFR 21 CFR 522.518
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
NCI_THESAURUS C802
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
Code System Code Type Description
WIKIPEDIA
Copper(II) glycinate
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
CAS
32817-15-5
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
ALTERNATIVE
CAS
5789-40-2
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
SUPERSEDED
EVMPD
SUB13502MIG
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
SMS_ID
100000079503
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
RXCUI
1428217
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY RxNorm
CAS
13479-54-4
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
NSC
162736
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID40893690
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
DAILYMED
68VAV8QID7
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
DRUG BANK
DB11509
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
ECHA (EC/EINECS)
236-783-2
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
PUBCHEM
3032611
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
NCI_THESAURUS
C83639
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
ECHA (EC/EINECS)
251-238-9
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
ALTERNATIVE
MERCK INDEX
m3887
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY Merck Index
CAS
142-51-8
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
SUPERSEDED
FDA UNII
68VAV8QID7
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY
MESH
C018493
Created by admin on Fri Dec 15 15:16:54 GMT 2023 , Edited by admin on Fri Dec 15 15:16:54 GMT 2023
PRIMARY